Thomas-Thi Pluess1, Daniel Hayoz2, Mette M Berger1, Luc Tappy3, Jean-Pierre Revelly1, Burkhard Michaeli1, Yvon A Carpentier4, René L Chioléro5. 1. Department of Intensive Care Medicine, CHUV, 1011, Lausanne, Switzerland. 2. Division of Hypertension and Vascular Medicine, CHUV, 1011, Lausanne, Switzerland. 3. Institute of Human Physiology, University of Lausanne, 1011, Lausanne, Switzerland. 4. Laboratory of Experimental Surgery, Université Libre de Bruxelles, Brussels, Belgium. 5. Department of Intensive Care Medicine, CHUV, 1011, Lausanne, Switzerland. rene.chiolero@chuv.ch.
Abstract
OBJECTIVE: To assess the effects of intravenous fish oil fat emulsion on the metabolic alterations induced by lipopolysaccharide (LPS) challenge in healthy volunteers. DESIGN:Two groups of eight healthy subjects were randomized to receive either two pharmacological doses of intravenous FO fat emulsion or no treatment. The FO group received twice 0.5 g/kg 10% emulsion (Omegaven) 48 and 24h before investigation. LPS (2 ng/kg) was injected as a bolus on the investigation day. Systemic parameters, indirect calorimetry, heart rate variability, and platelet membrane phospholipid composition were measured. RESULTS:Basal EPA and DHA content in platelet phospholipids was low (0.28% and 2.54%, respectively) and increased significantly after FO to 1.68% and 3.32%. LPS induced reproducible effects in all subjects. Fever was higher in the control [corrected] group than in FO group [corrected] the difference was significant from t (120) until t (360). FO blunted the neuroendocrine response: the rise in plasma norepinephrine was sevenfold lower at t (120) while the ACTH peak was fourfold lower. Tumor necrosis factor alpha was significantly lower between t (360) and t (180) in the FO group. CONCLUSIONS: Two doses of intravenous FO fat emulsion modified the phospholipid composition of platelets in healthy subjects. FO blunted fever and increased the neuroendocrine and the inflammatory responses to LPS.
RCT Entities:
OBJECTIVE: To assess the effects of intravenous fish oil fat emulsion on the metabolic alterations induced by lipopolysaccharide (LPS) challenge in healthy volunteers. DESIGN: Two groups of eight healthy subjects were randomized to receive either two pharmacological doses of intravenous FO fat emulsion or no treatment. The FO group received twice 0.5 g/kg 10% emulsion (Omegaven) 48 and 24h before investigation. LPS (2 ng/kg) was injected as a bolus on the investigation day. Systemic parameters, indirect calorimetry, heart rate variability, and platelet membrane phospholipid composition were measured. RESULTS: Basal EPA and DHA content in platelet phospholipids was low (0.28% and 2.54%, respectively) and increased significantly after FO to 1.68% and 3.32%. LPS induced reproducible effects in all subjects. Fever was higher in the control [corrected] group than in FO group [corrected] the difference was significant from t (120) until t (360). FO blunted the neuroendocrine response: the rise in plasma norepinephrine was sevenfold lower at t (120) while the ACTH peak was fourfold lower. Tumor necrosis factor alpha was significantly lower between t (360) and t (180) in the FO group. CONCLUSIONS: Two doses of intravenous FO fat emulsion modified the phospholipid composition of platelets in healthy subjects. FO blunted fever and increased the neuroendocrine and the inflammatory responses to LPS.
Authors: J J Pomposelli; E Flores; Y Hirschberg; T C Teo; G L Blackburn; S H Zeisel; B R Bistrian Journal: Am J Clin Nutr Date: 1990-09 Impact factor: 7.045
Authors: Hendrik Schmidt; Ursula Müller-Werdan; Thomas Hoffmann; Darrel P Francis; Massimo F Piepoli; Mathias Rauchhaus; Roland Prondzinsky; Harald Loppnow; Michael Buerke; Dirk Hoyer; Karl Werdan Journal: Crit Care Med Date: 2005-09 Impact factor: 7.598
Authors: Konstantin Mayer; Stephanie Gokorsch; Christine Fegbeutel; Katja Hattar; Simone Rosseau; Dieter Walmrath; Werner Seeger; Friedrich Grimminger Journal: Am J Respir Crit Care Med Date: 2003-02-25 Impact factor: 21.405
Authors: T C Teo; K M Selleck; J M Wan; J J Pomposelli; V K Babayan; G L Blackburn; B R Bistrian Journal: Metabolism Date: 1991-11 Impact factor: 8.694
Authors: Joo Y Lee; Anthony Plakidas; Won H Lee; Anne Heikkinen; Prithiva Chanmugam; George Bray; Daniel H Hwang Journal: J Lipid Res Date: 2002-12-01 Impact factor: 5.922
Authors: Sae Young Jae; Kevin S Heffernan; Soo-Hyun Park; Sun-Hae Jung; Eun Sun Yoon; Euy Jin Kim; Eui Soo Ahn; Bo Fernhall Journal: Clin Auton Res Date: 2010-05-01 Impact factor: 4.435
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-02-29 Impact factor: 17.440
Authors: Kie Kasuga; Rong Yang; Timothy F Porter; Nitin Agrawal; Nicos A Petasis; Daniel Irimia; Mehmet Toner; Charles N Serhan Journal: J Immunol Date: 2008-12-15 Impact factor: 5.422
Authors: Yann K Pittet; Mette M Berger; Thomas-Thi Pluess; Pierre Voirol; Jean-Pierre Revelly; Luc Tappy; René L Chioléro Journal: Intensive Care Med Date: 2009-10-21 Impact factor: 17.440
Authors: Martin D Rosenthal; Jayshil Patel; Kyle Staton; Robert G Martindale; Frederick A Moore; Gilbert R Upchurch Journal: Curr Gastroenterol Rep Date: 2018-08-04
Authors: Matthew Spite; Lucy V Norling; Lisa Summers; Rong Yang; Dianne Cooper; Nicos A Petasis; Roderick J Flower; Mauro Perretti; Charles N Serhan Journal: Nature Date: 2009-10-29 Impact factor: 49.962